REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel ...

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody ...

67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label ...

Jasper Therapeutics, Inc. announced promising preliminary results from its BEACON Phase 1b/2a study of briquilimab, an experimental therapy targeting mast cell-driven diseases like chronic spontaneous ...

REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody ...

Jasper Therapeutics (JSPR) is reporting positive updated clinical data from Jasper’s BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with CSU, as well as from the open label ...

Jasper expects to present full data from the SPOTLIGHT study in the first half of 2025. Jasper also announced that it expects to report initial data from all cohorts of the BEACON study in CSU during ...

Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ...

Enrollment in BEACON and SPOTLIGHT studies progressing faster than expected; enrollment in the 240mg single-dose cohort of the BEACON study ongoing Additional dosing cohort (180mg Q8W) added to BEACON ...